Literature DB >> 15285957

Physical health monitoring of patients with schizophrenia.

Stephen R Marder1, Susan M Essock, Alexander L Miller, Robert W Buchanan, Daniel E Casey, John M Davis, John M Kane, Jeffrey A Lieberman, Nina R Schooler, Nancy Covell, Scott Stroup, Ellen M Weissman, Donna A Wirshing, Catherine S Hall, Leonard Pogach, Xavier Pi-Sunyer, J Thomas Bigger, Alan Friedman, David Kleinberg, Steven J Yevich, Bonnie Davis, Steven Shon.   

Abstract

OBJECTIVE: Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general population. One approach to improving the health of patients with schizophrenia is to improve the monitoring of physical health that occurs in psychiatric settings. The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings.
METHOD: A consensus meeting including psychiatric and other medical experts assembled on October 17-18, 2002, to evaluate the existing literature and to develop recommendations for physical health monitoring of patients with schizophrenia. Conference participants reviewed the literature in the following areas: 1) weight gain and obesity; 2) diabetes; 3) hyperlipidemia; 4) prolongation of the QT interval on the ECG; 5) prolactin elevation and related sexual side effects; 6) extrapyramidal side effects, akathisia, and tardive dyskinesia; 7) cataracts; and 8) myocarditis. Experts for each topic area formulated monitoring recommendations that were discussed by all of the participants until a consensus was reached.
RESULTS: Consensus recommendations included regular monitoring of body mass index, plasma glucose level, lipid profiles, and signs of prolactin elevation or sexual dysfunction. Information from monitoring should guide the selection of antipsychotic agents. Specific recommendations were made for cardiac monitoring of patients who receive medications associated with QT interval prolongation, including thioridazine, mesoridazine, and ziprasidone, and for monitoring for signs of myocarditis in patients treated with clozapine. Patients who receive both first- and second-generation antipsychotic medications should be examined for extrapyramidal symptoms and tardive dyskinesia. Patients with schizophrenia should receive regular visual examinations.
CONCLUSIONS: The conference participants recommended that mental health care providers perform physical health monitoring that typically occurs in primary care settings for their patients who do not receive physical health monitoring in those settings. This change in usual practice is recommended on the basis of the conference participants' belief that this additional monitoring will result in the earlier detection of common, serious risk factors that could, without detection and intervention, contribute to impaired health of patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285957     DOI: 10.1176/appi.ajp.161.8.1334

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  162 in total

1.  Cholesterol, mood, and vascular health: Untangling the relationship: Does low cholesterol predispose to depression and suicide, or vice versa?

Authors:  Jess G Fiedorowicz; William G Haynes
Journal:  Curr Psychiatr       Date:  2010-07

2.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

3.  A case control study of the implementation of change model versus passive dissemination of practice guidelines for compliance in monitoring for metabolic syndrome.

Authors:  Dawn I Velligan; Desiree Castillo; Linda Lopez; Bren Manaugh; Charlotte Davis; Juanita Rodriguez; A Camis Milam; Albana Dassori; Alexander L Miller
Journal:  Community Ment Health J       Date:  2012-02-16

4.  Service users' views of moving on from early intervention services for psychosis: a longitudinal qualitative study in primary care.

Authors:  Helen Lester; Nagina Khan; Peter Jones; Max Marshall; David Fowler; Tim Amos; Max Birchwood
Journal:  Br J Gen Pract       Date:  2012-03       Impact factor: 5.386

Review 5.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

6.  Antipsychotic-induced movement disorders: evaluation and treatment.

Authors:  Maju Mathews; Sylvia Gratz; Babatunde Adetunji; Vinu George; Manu Mathews; Biju Basil
Journal:  Psychiatry (Edgmont)       Date:  2005-03

7.  The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.

Authors:  Davy Vancampfort; Joseph Firth; Christoph U Correll; Marco Solmi; Dan Siskind; Marc De Hert; Rebekah Carney; Ai Koyanagi; André F Carvalho; Fiona Gaughran; Brendon Stubbs
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

8.  Does a Physician's Attitude toward a Patient with Mental Illness Affect Clinical Management of Diabetes? Results from a Mixed-Method Study.

Authors:  Lisa C Welch; Heather J Litman; Christina P C Borba; Brenda Vincenzi; David C Henderson
Journal:  Health Serv Res       Date:  2014-12-09       Impact factor: 3.402

9.  Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.

Authors:  Martin Strassnig; Jean Miewald; Matcheri Keshavan; Rohan Ganguli
Journal:  Schizophr Res       Date:  2007-05-02       Impact factor: 4.939

10.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.